Epidermal Growth Factor Receptor Double Activating Mutations Involving Both Exons 19 and 21 Exist in Chinese Non-small Cell Lung Cancer Patients

Clinical Oncology

Volumn 19, Issue 7, 2007, Pages 499-506

  Zhang, G C ^a,b   Lin, J Y ^b   Wang, Z ^b   Zhou, Q ^b   Xu, C R ^b   Zhu, J Q ^a,b   Wang, K ^b   Yang, X N ^b   Chen, G ^b   Yang, J J ^b   Huang, Y J ^b   Liao, R Q ^b   Wu, Y L ^b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Autophosphorylation; epidermal growth factor receptor; mutation; non small cell lung cancer; targeted therapy; tyrosine kinase inhibitor

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR;

ADJUVANT THERAPY; ALLELE; ARTICLE; AUTOPHOSPHORYLATION; CANCER PATIENT; CANCER SURVIVAL; CELL LYSATE; CHINESE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; EXON; EXPRESSION VECTOR; FEMALE; GENE CONSTRUCT; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC SCREENING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MALE; MOLECULAR CLONING; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; WILD TYPE;

ADENOCARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34547519852     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.04.006     Document Type: Article

References (24)

1. Haura E.B. Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control 8 (2001) 326-336
2. Breathnach O.S., Freidlin B., Conley B., et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19 (2001) 1734-1742
3. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21 (2003) 2237-2246
4. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Am Med Assoc 290 (2003) 2149-2158
5. Perez-Soler R., Chachoua A., Hammond L.A., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22 (2004) 3238-3247
6. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
7. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
8. Shigematsu H., Lin L., Takahashi T., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 (2005) 339-346
9. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 (2005) e73
10. Choong N.W., Dietrich S., Seiwert T.Y., et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation. Nat Clin Pract Oncol 3 (2006) 50-57
11. Zhang X.T., Li L.Y., Mu X.L., et al. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol 16 (2005) 1334-1342
12. Mu X.L., Li L.Y., Zhang X.T., et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin Cancer Res 11 (2005) 4289-4294
13. Sriuranpong V., Chantranuwat C., Huapai N., et al. High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand. Cancer Lett 239 (2006) 292-297
14. Yokoyama T., Kondo M., Goto Y., et al. EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci 97 (2006) 753-759
15. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 (2004) 13306-13311
16. Hsieh R.K., Lim K.H., Kuo H.T., Tzen C.Y., and Huang M.J. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 128 (2005) 317-321
17. Sasaki H., Endo K., Konishi A., et al. EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res 11 (2005) 2924-2929
18. Grunwald V., and Hidalgo M. The epidermal growth factor receptor: a new target for anticancer therapy. Curr Probl Cancer 26 (2002) 109-164
19. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 Suppl 4 (2001) S3-S8
20. Gazdar A.F., Shigematsu H., Herz J., and Minna J.D. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?. Trends Mol Med 10 (2004) 481-486
21. Huse M., and Kuriyan J. The conformational plasticity of protein kinases. Cell 109 (2002) 275-282
22. Raymond E., Faivre S., and Armand J.P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 Suppl 1 (2000) 15-23 41-42
23. Sordella R., Bell D.W., Haber D.A., and Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (2004) 1163-1167
24. Albanell J., Rojo F., Averbuch S., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20 (2002) 110-124